Background: Tramadol poisoning is one of the major health problems worldwide especially in developing countries. Seizure is considered a serious and life-threatening manifestation of acute tramadol overdose. Recently, serum S100B protein has been shown to be a useful and specific neuro-biochemical marker of central nervous system damage. Aim of the study: To assess the role of serum S100B protein on admission as a predictor of seizure occurrence in patients with acute tramadol poisoning and to determine the factors affecting tramadol-induced seizure. Participants and methods: Thirty-three patients with acute tramadol poisoning, of both sexes, and 20 healthy sexand age-matched volunteers as a control group were included in this study. The studied tramadol poisoned patients were classified into two groups; group I: Seizure group and group II: Non-seizure group. For all patients, demographic and poisoning data were recorded then clinical evaluation and investigations were performed. Serum S100B level was estimated on admission. Results: : There was a statistically significant difference between patients with seizures and patients without seizures regarding age group, gender, ingested tramadol dose, Glasgow coma scale (GCS), poisoning severity score (PSS) and administered naloxone dose. On the other hand, there was no significant difference between both groups in manner of poisoning, delay time, vital data, oxygen saturation, arterial blood gases & pH and hospitalization period. The mean serum S100B was significantly higher in tramadol poisoned patients when compared to the control group; moreover, it was significantly elevated in patients with seizures than patients without seizures. Serum S100B as a predictor of seizures showed AUC =0.863 (p=<0.001) at cut-off value >0.58 µg/L with 75 % sensitivity and 95.24 % specificity. Conclusion: Serum S100B could be used as a good predictor of tramadol-induced seizure and it could be useful to assess clinical severity in acute tramadol overdose. Moreover, young adult males, increased ingested tramadol dose, increased administered naloxone dose and decreased level of consciousness are considered risk factors of tramadol-induced seizures.
INTRODUCTION
Currently, opioids uses and their related morbidity and mortality are being one of the major health problems worldwide (Eizadi-Mood et al., 2014). Tramadol is atypical, synthetic and centrally-acting analgesic that is related to codeine and morphine in structure Tramadol was ranked as a second cause of acute poisoning after oxycodone in annual reports of the American Association of Poison Control Centers Toxic Exposure Surveillance (Watson et al., 2003 There is limited information about factors affecting tramadol-induced seizure and no available data evaluating the role of serum S100B in acute tramadol poisoning. Therefore, this study aimed to assess the role of serum S100B protein, on admission, as a predictor of seizure in patients with acute tramadol poisoning and to determine the factors affecting tramadol-induced seizures. 
PARTICIPANTS & METHODS

Study design and ethical points:
This prospective study was conducted on thirty-three patients, of both sexes, with acute tramadol poisoning who were admitted to Tanta Toxicological Unit during the period from July 2014 to June 2015 and 20 healthy sexand age-matched volunteers as a control group. The study was approved by Research Ethics committee of Tanta Faculty of Medicine. Written informed consents were obtained from adult conscious participants or guardians of teenagers after complete description of the study. All patients' data were recorded in special sheets and the privacy and confidentiality of these data and records were ascertained through coding system.
Patients:
All patients aged 18 years or more, of both sexes, with acute tramadol poisoning admitted within 24 hours, during the study period, were included. Exclusion criteria included: patients with previous or family history of epilepsy, traumatic head injuries, neuropsychiatric disorders and patients with history of other poisonings or drug co-ingestion as well as patients with positive urine screen test for substance abuse including; benzodiazepines, barbiturates, opiates, methadone, amphetamine and tricyclic antidepressants.
Furthermore, transferred patients from other hospitals, patients with systemic comorbidities including metabolic, endocrinal or cardiac causes and infections were also excluded from the study.
Electrocardiography (ECG), head computed tomography (CT) scan and laboratory investigations including liver and renal function tests, complete blood count (CBC), random blood glucose level, sodium (Na) and potassium (K) levels were performed for every participant to exclude the patients who did not fulfill the criteria of the study.
Diagnosis of tramadol poisoning was based on history, characteristic symptoms & signs and, urinary screening analysis of tramadol. The studied tramadol poisoned patients were classified into two groups; Group I (Seizure group; patients having seizures) and Group II (Non-seizure group; patients do not having seizures). Diagnosis of seizure was based on jerky movements of the whole body, tonic/clonic spasms and convulsions (Eizadi-Mood et al., 2014). All volunteers of the control group gave negative history for taking any drugs and had negative urinary immunoassay for substances of abuse.
Methods:
For all patients, demographic data (age, sex, time of admission), poisoning data (name of drug, dose, route of exposure, mode of poisoning, delay time between exposure and arrival to hospital "pre-hospitalization period") and onset of seizures were recorded.
Clinical evaluation was performed for all patients including initial vital signs (blood pressure, pulse rate, respiratory rate and temperature), initial Glasgow Coma Scale (GCS), and poisoning severity score (PSS). Additionally, the administered naloxone dose, endotracheal intubation need and hospitalization period were documented. Serum S100B level, arterial blood gases (ABG) and pH were measured for all patients on admission and before treatment. Three milliliters venous blood samples for S100B estimation were collected immediately on admission in plain test tubes. The whole blood was allowed to clot at room temperature for 30 min. Then, the samples were centrifuged at 3000 rpm for 10 min. Following centrifugation, the serum was separated and deeply stored at -80 ºC until analysis for maximum of 6 months.
Quantification of human serum S100B protein was performed in accordance with the direction of manufacture by double antibody sandwich enzyme linked immunosorbent assay (ELISA) using Human S100B ELISA kit (Shanghi Sunred Biological Technology Co., Ltd, Shanghai, China). The results were expressed as µg/L. Also, one-milliliter arterial blood sample was taken on heparinized tube for estimation of arterial blood gases and pH.
Moreover, 20 ml of urine samples were collected from each patient on admission in clean dry sterile disposable containers, labelled with patient's name, serial number and date of taking the sample then were preserved at -20ºC.
Urine screening analysis was done for detection of tramadol and to exclude any other drugs or substances of abuse such as benzodiazepines, opiates, barbiturates, cocaine, cannabinoids and amphetamines by using (Quick Profile™ DOA/Alcohol Panel Test Device; Lumi Quick Diagnostic Inc., Santa Clora, CA, USA); which is an immunoassay based one step drug of abuse rapid in-vitro test in human urine.
Statistical analysis
The collected data were organized and statistically analyzed using SPSS 
RESULTS
Thirty-three patients with acute tramadol poisoning were included in this study. The ages of the studied patients ranged from 18 to 46 years with a mean age 25.6 ± 9.3 years and most of the studied patients were young adult males aged between 21 to 40 years (63.6%). Toxicological data revealed that, the route of exposure was oral in all cases. The majority of cases (63.6%) were intoxicated due to suicidal attempts followed by tramadol abusers (27.3%). The mean delay time was 5.3 ± 2.1 hours. The ingested tramadol dose in the studied patients ranged from 150 to 3000 mg with a Moreover, the median of administered naloxone dose in the studied patients was 2.4 mg (range 0.4 -10.8 mg). The administered naloxone doses were significantly higher in patients with seizures than in patients without seizures with median of 6.8 vs 2.4 mg respectively (p < 0.017). Only three patients (9.1%) required endotracheal intubation with no significant difference between the two studied groups (table 3) .
As shown in table 3, the mean serum S100B of the studied patients was 0.50 ± 0.13 (0.30 -0.81 µg/L). It was significantly higher than that of the control group 0.08 ± 0.02 (0.02 -0.1 µg/L). Also, the mean serum S100B was significantly higher in patients with seizures than in patients without seizures (p <0.001).
Egypt J. Forensic Sci. Appli. Toxicol Vol 16(2) December 2016 Likewise, serum S100B showed significant positive correlations with delay time, PSS, administered naloxone dose and a significant negative correlation with GCS. However, no significant correlations could be detected between serum S100B and ingested tramadol dose, intubated cases or hospitalization period (table 4) The current study demonstrated that the ingested tramadol dose in seizure group ranged from 200 to 3000 mg with median of 1200 mg, which was significantly higher than cases without seizures. This result partially agreed with Taghaddosinejad et al. The present study revealed that, the mean delay time was longer in seizure group than in non-seizure group (6.3 ± 2.6 vs 4.8 ± 1.6 hours respectively). This partially agreed with Rahimi et al.
(2014) who demonstrated significant increase in delay time in seizure cases than cases without seizure (330.3 ± 53.5 vs. 257.3 ± 30.1 min respectively).
Additionally, intentional poisoning was the most common mode of poisoning followed by drug abuse in our study. This finding is in agreement with The majority of patients in the present study had signs of respiratory depression as bradypnea, respiratory acidosis in 54.5% per each and hypoxia in 63.7% of the studied patients. To the best of the authors' knowledge, the present study was the first study to assess the role of S100B protein as a predictor of tramadol induced seizure. The current study demonstrated that, patients with acute tramadol overdose with and without seizures had significantly higher serum S100B levels when compared to the control group. Similarly, Ambrozic et al. (2008) found that serum S100B was significantly higher in acute benzodiazepine patients when compared to control group.
Moreover, patients with seizures had significantly higher serum S100B than those without seizures. Many previous studies have documented elevation of serum S100B in patients Furthermore, serum S100B might be released to peripheral circulation as a result of hypoxic brain damage. Since, serum S100B is found in high concentration of astroglial cells, which are very sensitive to hypoxic stress. Therefore, serum S100B may indirectly reflect neuronal damage (Bottiger et al., 2001). This could be supported by significant increase of serum S100B in patients who had low Glascow coma scale (GCS) and severe poisoning severity score (PSS) on admission. Additionally, the majority of patients in the present study had signs of respiratory depression and hypoxia. Previous studies have reported the diagnostic and prognostic value of serum S100B in brain hypoxia due to carbon monoxide poisoning, benzodiazepine overdose, organophosphate poisoning and aluminum neurotoxicity (Ambrozic et al., 2008; Yardan et al., 2009 and Cakir et al., 2010). The role of tissue hypoperfusion, in the elevation of serum S100B, in the current study was unlikely as the majority of cases (90.9%) had normal blood pressure.
Moreover, ROC curve analysis showed that high serum S100B might be useful in prediction of tramadolinduced seizure. Above the cutoff value of 0.58 µg/L, serum S100B had 75 % sensitivity and 95.24 % specificity. This means that above level of 0.58 µg/L, S100B could predict seizures in 75% of cases and below these level, seizures could be excluded in 95.24 % of cases.
CONCLUSIONS:
Although tramadol seems to be a safe analgesic, it might cause subtle brain injury. Serum S100B is a good predictor of tramadol-induced seizure and it could be used as a useful biomarker to assess clinical severity in acute tramadol overdose. Additionally, young adult males increased both of ingested tramadol doses and administered naloxone dose, decreased level of consciousness and severe tramadol poisoning were considered risk factors of tramadol-induced seizure.
LIMITATION OF THE STUDY& RECOMMENDATIONS
One of the limitations in this study was our inability to follow up the patients which prevented us from evaluation of the prognostic value of serum S100B in delayed neurological sequelae after patient's discharge. Other limitations are the small sample size and absent tramadol blood level which prevented us from clarifying its role in seizure incidence. Therefore, we suggested performing a larger prospective study for acute tramadol poisoned patients taking into consideration a good follow up to evaluate the role of serum S100B as a diagnostic and prognostic biomarker. Also, we suggested serial measurements of serum S100B to be performed to verify the best time of sampling in acute tramadol poisoning.
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